EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ribonucleotide reductase inhibition improves the symptoms of a Caenorhabditis elegans model of Alzheimer's disease

Ana M Brokate-Llanos, Mireya Sanchez-Ibañez, Mercedes M Pérez-Jiménez, José M Monje-Moreno, Carlos Gómez-Marín, Carlos Caro, Carlos Vivar-Rios, Miguel A Moreno-Mateos, María L García-Martín, Manuel J Muñoz iD, José L Royo

G3: Genes, Genomes, Genetics · 07.05.2024 · 14 (5)

DOI: 10.1093/g3journal/jkae040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift G3: Genes, Genomes, Genetics, online erschienen am 27.02.2024. Verfasst von Ana M Brokate-Llanos und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centro Andaluz de Biologia del Desarrollo, University Pablo de Olavide-CISC-Junta de Andalucía, Ctra Utrera Km 1, Sevilla 41013, Spain. Hauptthemen laut MEDLINE: Caenorhabditis elegans, Alzheimer Disease, Disease Models, Animal, Deoxycytidine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, Fondo Europeo de Desarrollo Regional, Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease is the main cause of aging-associated dementia, for which there is no effective treatment. In this work, we reanalyze the information of a previous genome wide association study, using a new pipeline design to identify novel potential drugs. With this approach, ribonucleoside-diphosphate reductase gene (RRM2B) emerged as a candidate target and its inhibitor, 2′, 2′-difluoro 2′deoxycytidine (gemcitabine), as a potential pharmaceutical drug against Alzheimer's disease. We functionally verified the effect of inhibiting the RRM2B homolog, rnr-2, in an Alzheimer's model of Caenorhabditis elegans, which accumulates human Aβ1-42 peptide to an irreversible paralysis. RNA interference against rnr-2 and also treatment with 200 ng/ml of gemcitabine, showed an improvement of the phenotype. Gemcitabine treatment increased the intracellular ATP level 3.03 times, which may point to its mechanism of action. Gemcitabine has been extensively used in humans for cancer treatment but at higher concentrations. The 200 ng/ml concentration did not exert a significant effect over cell cycle, or affected cell viability when assayed in the microglia N13 cell line. Thus, the inhibitory drug of the RRM2B activity could be of potential use to treat Alzheimer's disease and particularly gemcitabine might be considered as a promising candidate to be repurposed for its treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Caenorhabditis elegansAlzheimer DiseaseDisease Models, AnimalDeoxycytidineAnimalsAmyloid beta-PeptidesHumansGemcitabineRibonucleoside Diphosphate ReductaseRibonucleotide ReductasesAdenosine TriphosphateCaenorhabditis elegans ProteinsEnzyme InhibitorsRNA Interference

Stichwörter der Autor:innen

Caenorhabditis elegansAlzheimerRRM2Bgemcitabine

Substanzen

DeoxycytidineAmyloid beta-PeptidesGemcitabineRibonucleoside Diphosphate ReductaseRibonucleotide ReductasesAdenosine TriphosphateCaenorhabditis elegans ProteinsEnzyme Inhibitors

Autor:innen und Institutionen

  • Centro Andaluz de Biologia del Desarrollo, University Pablo de Olavide-CISC-Junta de Andalucía, Ctra Utrera Km 1, Sevilla 41013, Spain.
  • Department of Surgery, Immunology and Biochemistry, School of Medicine, University of Malaga, Boulevar Louis Pasteur s/n, Málaga 29010, Spain.
  • Andalusian Centre for Nanomedicine and Biotechnology (Junta de Andalucía-Universidad de Málaga), BIONAND, Málaga 29590, Spain.

ORCID-Profile: Manuel J Muñoz

Förderung

  • NIH HHS
  • Fondo Europeo de Desarrollo Regional
  • Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía
  • Spanish Ministry of Science
  • MCIN
  • AEI
  • University Pablo de Olavide, and Junta de Andalucía

Zitieren

APA

Brokate-Llanos, A. M., Sanchez-Ibañez, M., Pérez-Jiménez, M. M., Monje-Moreno, J. M., Gómez-Marín, C., Caro, C., Vivar-Rios, C., Moreno-Mateos, M. A., García-Martín, M. L., Muñoz, M. J., & Royo, J. L. (2024). Ribonucleotide reductase inhibition improves the symptoms of a Caenorhabditis elegans model of Alzheimer's disease. G3: Genes, Genomes, Genetics, 14(5). https://doi.org/10.1093/g3journal/jkae040

Vancouver

Brokate-Llanos AM, Sanchez-Ibañez M, Pérez-Jiménez MM, Monje-Moreno JM, Gómez-Marín C, Caro C, et al. Ribonucleotide reductase inhibition improves the symptoms of a Caenorhabditis elegans model of Alzheimer's disease. G3: Genes, Genomes, Genetics. 2024;14(5). doi:10.1093/g3journal/jkae040

BibTeX
@article{BrokateLlanos2024,
  author = {Brokate-Llanos, Ana M and Sanchez-Ibañez, Mireya and Pérez-Jiménez, Mercedes M and Monje-Moreno, José M and Gómez-Marín, Carlos and Caro, Carlos and Vivar-Rios, Carlos and Moreno-Mateos, Miguel A and García-Martín, María L and Muñoz, Manuel J and Royo, José L},
  title = {Ribonucleotide reductase inhibition improves the symptoms of a Caenorhabditis elegans model of Alzheimer's disease},
  journal = {G3: Genes, Genomes, Genetics},
  year = {2024},
  volume = {14},
  number = {5},
  doi = {10.1093/g3journal/jkae040}
}
Kostenlos starten →